Patents by Inventor Carl T. Wild
Carl T. Wild has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11236122Abstract: The present invention concerns novel pharmaceutically active triterpene amine derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the triterpene amine compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C-28 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus-1 (HIV-1).Type: GrantFiled: June 28, 2019Date of Patent: February 1, 2022Assignees: DFH THERAPEUTICS, The United States Of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Theodore J. Nitz, Carl T. Wild, David E. Martin, Eric O. Freed
-
Publication number: 20210253627Abstract: The present invention concerns novel pharmaceutically active triterpene amine derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the triterpene amine compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C-28 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus-1 (HIV-1).Type: ApplicationFiled: June 28, 2019Publication date: August 19, 2021Inventors: Theodore J. NITZ, Carl T. WILD, David E. MARTIN, Eric O. FREED
-
Patent number: 8318425Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme.Type: GrantFiled: July 6, 2009Date of Patent: November 27, 2012Assignees: The United States of America, as represented by the Secretary, Department & Human Services, Myrexis, Inc.Inventors: Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
-
Publication number: 20110142847Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.Type: ApplicationFiled: October 30, 2007Publication date: June 16, 2011Applicants: Panacos Pharmaceuticals, Inc., GOVERNMENT OF THE U.S., REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Carl T. Wild, Carol D. Weiss
-
Publication number: 20100291680Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.Type: ApplicationFiled: June 2, 2010Publication date: November 18, 2010Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, JR., Alphonse J. Langlois
-
Publication number: 20100221264Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme.Type: ApplicationFiled: July 6, 2009Publication date: September 2, 2010Applicants: Panacos Pharmaceuticals, Inc., The Govt. of the U.S.A. as represented by the Secretary, Dept. of Health & Human ServicesInventors: Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
-
Patent number: 7537765Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme.Type: GrantFiled: May 24, 2004Date of Patent: May 26, 2009Assignees: Panacos Pharmaceuticals, Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
-
Publication number: 20080233559Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme.Type: ApplicationFiled: December 21, 2007Publication date: September 25, 2008Inventors: Karl SALZWEDEL, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
-
Publication number: 20080200550Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme.Type: ApplicationFiled: May 24, 2005Publication date: August 21, 2008Applicants: V.I. TECHNOLOGIES, INC., THE GOV. OF US AS REP. BY THE SEC. DEP. OF HEALTHInventors: Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
-
Patent number: 7365221Abstract: Betulin and dihydrobetulin acyl derivatives according to the present invention have been found to have potent anti-HIV activity. The compounds of the present invention have Formula I as described herein, or pharmaceutically acceptable salts thereof; wherein R1 is a C2-C20 substituted or unsubstituted carboxyacyl or ester thereof; R2 is hydrogen, halogen, hydroxyl or —OR3, R3 is C2-C20 substituted or unsubstituted carboxyacyl; and R4 is hydrogen or C(C6H5)3; wherein the dashed line represents an optional double bond between C20 and C29.Type: GrantFiled: June 18, 2004Date of Patent: April 29, 2008Assignees: Panacos Pharmaceuticals, Inc., The University of North Carolina at Chapel Hill, Niigata University of Pharmacy and Applied Life SciencesInventors: Graham P. Allaway, Carl T. Wild, Yoshiki Kashiwada, Kuo-Hsiung Lee
-
Patent number: 7311916Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.Type: GrantFiled: September 10, 2003Date of Patent: December 25, 2007Assignees: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, Panacos Pharmaceuticals, Inc.Inventors: Carl T. Wild, Carol D. Weiss
-
Patent number: 7273614Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.Type: GrantFiled: October 9, 2002Date of Patent: September 25, 2007Assignee: Duke UniversityInventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild
-
Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
Patent number: 7122190Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.Type: GrantFiled: October 9, 2002Date of Patent: October 17, 2006Assignee: Duke UniversityInventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, Alphonse J. Langlois -
Publication number: 20040265320Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme.Type: ApplicationFiled: January 29, 2004Publication date: December 30, 2004Inventors: Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
-
Patent number: 6824783Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.Type: GrantFiled: June 7, 1995Date of Patent: November 30, 2004Assignee: Duke UniversityInventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild
-
Publication number: 20040213801Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.Type: ApplicationFiled: September 10, 2003Publication date: October 28, 2004Applicant: Panacos Pharmaceuticals, Inc.Inventors: Carl T. Wild, Carol D. Weiss
-
Patent number: 6768007Abstract: 3′,4′-di-O-camphanoyl-(+)-cis-khellactone analogs according to the present invention have been found to have anti-HIV activity. The compounds of the present invention have the following formula: or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein R1, R2, R3, R4, X, and Z are set in the specification. The invention is also directed to pharmaceuticals compositions comprising one or more compounds of Formula I, optionally further comprising one or more anti-viral agents or immunostimulating agents. Further, the invention is directed to the use of compounds of Formula I for the inhibition of a retroviral infection in cells or tissue of an animal, for the treatment of a patient suffering from a retroviral-related pathology, for the prevention of transmission of HIV infection from an HIV infected pregnant woman to a fetus, and for the prevention of transmission of HIV infection during sexual intercourse.Type: GrantFiled: March 13, 2002Date of Patent: July 27, 2004Assignees: Panacos Pharmaceuticals, Inc., The University of North Carolina at Chapel HillInventors: Kuo-Hsiung Lee, Lan Xie, Graham P. Allaway, Carl T. Wild
-
Publication number: 20040131629Abstract: Betulin and dihydrobetulin acyl derivatives according to the present invention have been found to have potent anti-HIV activity. The compounds of the present invention have Formula I as described herein, or pharmaceutically acceptable salts thereof, wherein R1 is a C2-C20 substituted or unsubstituted carboxyacyl, R2 is hydrogen, chloro, bromo, or hydroxy, R4 is hydrogen or C(C6H5)3; wherein the dashed line represents an optional double bond between C20 and C29.Type: ApplicationFiled: September 26, 2003Publication date: July 8, 2004Applicants: Panacos Pharmaceuticals, Inc., The University of North Carolina at Chapel Hill, Niigata University of Pharmacy and Applied ScienceInventors: Graham P. Allaway, Carl T. Wild, Yoshiki Kashiwada, Kuo-Hsiung Lee
-
Publication number: 20040132011Abstract: The invention is directed to methods for identifying compounds that decrease the ability of a virus, such as HIV-1, to infect previously uninfected cells by inducing conformational changes in viral envelope proteins, and the compounds discovered by such methods.Type: ApplicationFiled: October 16, 2003Publication date: July 8, 2004Applicant: Panacos Pharmaceuticals, Inc.Inventors: Graham P. Allaway, Carl T. Wild, Karl Salzwedel
-
Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
Publication number: 20040052820Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.Type: ApplicationFiled: October 8, 2002Publication date: March 18, 2004Applicants: Duke University, Trimeris, Inc.Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O?apos;Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, Alphonse J. Langlois